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Abstract 
Despite its natural healing potential, bone is unable to regenerate sufficient tissue within, critical-
sized defects resulting in a non-union of bone ends. As a consequence, interventions are required 
to replace missing, damaged or diseased bone. Bone grafts have been widely employed for the 
repair of such critical-sized defects. However, the well-documented drawbacks associated with 
autografts, allografts and xenografts have motivated the development of alternative treatment 
options. Traditional tissue-engineered constructs typically attempt to direct in vitro bone-like 
matrix formation prior to implantation into bone defects, mimicking the embryological process 
of intramembranous ossification (IMO). Commonly, tissue-engineered constructs developed 
using this approach inevitably fail once implanted due to poor perfusion leading to avascular 
necrosis and core degradation. Due to such drawbacks, an alternative tissue engineering strategy 
based on endochondral ossification (ECO) has begun to emerge which involves the use of in 
vitro tissue-engineered cartilage as a transient biomimetic template to facilitate bone formation 
within large defects. This is driven by the hypothesis that hypertrophic chondrocytes can secrete 
angiogenic factors and alkaline phosphatase which play pivotal roles in both the vascularization 
of constructs in vivo and the deposition of a mineralized extracellular matrix with resulting bone 
deposition. In this context, this review will focus on current strategies taken to recapitulate ECO 
using a range of distinct cells, biomaterials and biochemical stimuli in order to facilitate in vivo 
bone formation.   
 
Keywords: Bone; intramembranous ossification; endochondral ossification; hypertrophy; 
mesenchymal stem cells 
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1.1. Introduction 
Bone, the second most commonly transplanted tissue worldwide after blood products (Shegarfi 
and Reikeras, 2009), is a highly vascularized tissue, unique in its capacity to self-regenerate 
without the formation of a fibrotic scar (Marsell and Einhorn, 2011). Despite its natural healing 
potential, native bone is not always able to repair large-scale defects which can result in 
permanent bone loss and fracture non-union. Consequently interventions such as bone grafting 
are required to replace damaged or diseased bone resulting in more than 1 million bone repair 
surgeries and between 500,000 to 600,000 bone-grafting procedures carried out annually in the 
United States (Cheung, 2005, Marino and Ziran, 2010). Autogenous bone grafting, also known 
as autografting, represents the clinical “gold standard” due to its high immuno-compatibility and 
naturally osteoinductive, osteoconductive and osteogenic properties (Khan et al., 2005). 
However, the drawbacks associated with this approach include donor site morbidity, limited graft 
supply, a decrease in the regenerative capacity of graft material with an increase in donor age, as 
well as donor-to-donor variability. Allografting donor tissue from another individual is less 
frequently undertaken due to the risk of immune rejection, disease transmission and the potential 
for chronic inflammation. Xenografting of tissues or organs derived from a non-human animal 
source into a human recipient is also associated with similar drawbacks such as infection, 
rejections and chronic inflammation. These limitations have motivated the development of 
alternative treatment options (Grabowski and Cornett, 2013, Muller et al., 2013). 
 
The generation of tissue-engineered autologous constructs using a combination of cells derived 
from a patient and an optimized biomaterial would avoid many of the drawbacks associated with 
autografting and allografting. Despite numerous efforts in the area of bone tissue engineering 
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(TE), a mechanically competent, vascularized construct that is capable of supporting defect 
repair with fully functional regenerated bone tissue has yet to be developed (Johnson et al., 
2011). Bone graft substitutes represent an alternative approach for the treatment of bone loss.  
However, commercially available bone graft substitutes have shown limited clinical success in 
human trials ensuring autogenous bone grafting approaches continue to account for the majority 
of bone graft procedures, regardless of the significant associated risks and costs (Grabowski and 
Cornett, 2013).  
 
Traditional tissue-engineered constructs are produced by culturing cells on biodegradable 
biomaterial scaffolds in media containing osteogenic factors to stimulate in vitro bone-like 
matrix formation prior to implantation into bone defects in vivo, mimicking the embryological 
process of intramembranous ossification. However, extensive surface matrix deposition in vitro, 
diffusion limitations and the lack of a vascular network hamper nutrient delivery and waste 
removal from the centre of such TE constructs, resulting in poor perfusion, avascular necrosis 
and core degradation in vivo (Lyons et al., 2010, Kelly and Prendergast, 2005, Tremblay et al., 
2005, Ko et al., 2007, Phelps and Garcia, 2009). As a result, traditional tissue-engineered 
constructs which appear to demonstrate great potential in vitro often fail once implanted. This 
creates a major challenge in the field of TE and several strategies to improve osteogenesis and 
construct vascularization have been investigated including the delivery of angiogenic 
biomolecules (Fuchs et al., 2012, Rivron et al., 2012, Kanczler et al., 2010), hypoxic culture 
(Wise et al., 2013, Zou et al., 2012), flow perfusion (Barron et al., 2012, Keogh et al., 2011) and 
in vitro  vascularization of scaffolds (Liu et al., 2012, Duffy et al., 2011, Tsigkou et al., 2010, 
McFadden et al., 2013). However, an optimal approach has yet to be clearly identified. 
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Recently, there has been a move towards recapitulating the process of endochondral ossification 
in the field of TE through the use of engineered cartilage as transient templates to promote 
healing in bone defects (Fig. 1). Bone repair strategies based on endochondral priming may be 
able to harness this progression to provide the structural, cellular, angiogenic and osteogenic 
factors required to facilitate vascularization, bone regeneration and fracture healing (Kanczler 
and Oreffo, 2008, Dickson et al., 1995, Trueta and Amato, 1960). In this context, such advances 
in bone tissue engineering that aim to recapitulate the process of endochondral ossification in the 
repair of bone defects will be the focus of this review. 
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Figure 1. Endochondral tissue engineering strategies for bone regeneration. Tissue engineered 
cartilage can be generated in vitro to act as a transient biomimetic template capable of secreting 
trophic biomolecules beneficial to bone formation. Current approaches to in vitro cartilage 
production include self-assembly systems using transwell plates, cell seeding onto biomaterial 
scaffolds and cell pellet culture. Following implantation into skeletal defects, this cartilage 
templates can provide the structural, cellular and angiogenic stimuli required for the formation of 
nascent vascularized bone capable of restoring tissue form and function to its pre-injury state. 
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1.2. Embryonic bone development and fracture healing: the role of endochondral 
ossification 
Bone development occurs by two distinct processes: intramembranous ossification (IMO) and 
endochondral ossification (ECO). IMO forms most of the bones that make up the craniofacial 
skeleton. This process is characterized by mesenchymal stem cells (MSCs) differentiating 
directly into osteoblasts and eventually producing bone. Unlike IMO, ECO is characterized by a 
cartilaginous template anlage and is responsible for the formation of long bones as well as their 
elongation during growth and fracture healing (Gerstenfeld et al., 2003). This dynamic process 
involves several stages, many of which occur concurrently, both temporally and spatially. ECO 
begins with MSCs undergoing condensation and differentiating into chondrocytes which secrete 
an extracellular matrix (ECM) that forms a hyaline cartilage template (Fig. 2). The template 
grows interstitially and cells derived from the inner aspect of the perichondrium undergo direct 
osteoblastic differentiation and secrete mineralized tissue that forms the bone collar, 
subsequently becoming cortical bone. Meanwhile, chondrocytes in the cartilage template 
proliferate, mature and undergo hypertrophy secreting collagen type X matrix, angiogenic factors 
such as vascular endothelial growth factor (VEGF), as well as the enzyme alkaline phosphatase 
with resulting mineralized tissue deposition. Matrix metalloproteinase activity is required at this 
stage to degrade the cartilaginous template thereby making it permissive of blood vessels which 
invade the diaphysis. These vessels deliver osteoclasts and osteoprogenitor cells thereby forming 
the primary ossification centre (POC). The calcified cartilage template is partially resorbed by 
recruited osteoclasts and woven bone is laid down. While the diaphysis is remodeled to form a 
medullary cavity, a secondary ossification centre (SOC) is formed in the epiphyses, with the 
periphery of the bone ends maintaining the stable superficial hyaline articular cartilage tissue 
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seen within diarthroidal joints. Between the primary and secondary ossification centers, an 
epiphyseal/growth plate persists and is composed of cartilage tissue that continuously grows and 
is replaced by bone thereby regulating elongation of bones.  
 
 
Figure 2. Overview of endochondral bone development. (A) At the beginning of bone formation, 
mesenchymal stem cells condense together before (B) undergoing chondrogenic differentiation 
to form the hyaline cartilage template of future long bones. MSCs located on the periphery form 
the perichondrium. (C) Cells in the centre of template undergo hypertrophy while cells located 
on the periphery undergo direct osteoblastic differentiation to form an encircling bone collar. (D) 
Hypertrophic cells initiate mineralisation of the cartilage rudiment. The diaphysis is invaded by 
the ossification front of blood vessels and influxing cells resulting in the formation of the 
primary ossification centre (POC). Osteoclasts remodel the calcified cartilage template while 
osteoprogenitor develop into osteoblasts and lay down the osteoid of developing bone. (E&F) In 
early postnatal life the developing bone ends, the epiphyses, are invaded by blood vessels leading 
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to the formation of the secondary ossification centre (SOC) with the periphery maintaining a 
stable cartilage phenotype resulting in hyaline articular surfaces seen within joints. The 
epiphyseal growth plate persists between the POC and SOC. It is the sight longitudinal bone 
growth before ossifying in adulthood. 
 
From a clinical perspective, the majority of bone fracture healing occurs by secondary/indirect 
healing in which a transient soft callus composed of a cartilaginous template is an important 
intermediate for normal repair, analogous to endochondral bone formation (Ito and Perren, 
2007). Following the initial inflammatory phase involving blood vessels disruption, macrophage 
and poly-morphonuclear neutrophils release and migration into the fracture site, the fracture 
hematoma is replaced by granulation tissue with osteoclasts degrading necrotic bone. Progenitor 
cells that originate from the periosteum differentiate into osteoblasts thereby stimulating 
appositional growth and enveloping the defect. The callus is invaded by MSCs that differentiate 
into chondrocytes and synthesize a cartilaginous ECM which undergoes ECO to form calcified 
tissue that results in woven bone. Therefore, TE strategies that can mimic the natural progression 
of bone growth and healing could provide a therapeutic option due to their production of trophic 
and pro-angiogenic factors that can stimulate cell migration and vascularization in areas bone 
loss resulting in enhanced regeneration.  
 
1.3. Regulation of remodeling and neo-vascularization in endochondral ossification 
As previously mentioned two critical steps during endochondral ossification are the vascular 
invasion and remodeling of the cartilage anlage. A functional vascular network is essential to 
overcome diffusion limitations in the enlarging cartilage template that would result in death of 
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the inner cell populations (Lovett et al., 2009). Moreover, vessel ingrowth allows osteoclasts and 
osteoprogenitor cells access to inner aspect of the developing bone and marks the beginning of 
ossification. As chondrocytes undergo hypertrophy, they enlarge in size with a 5- to 10-fold 
increase in mean cell volume (Hunziker et al., 1999, Noonan et al., 1998) (Fig. 3). To 
compensate for this increase in size, hypertrophic chondrocytes secrete MMP-13 which degrades 
the ECM surrounding the cells that is rich in fibrillar collagen (Mackie et al., 2008). MMP-9 is 
also secreted by the cells to degrade aggrecans (Cawston and Wilson, 2006). This remodeling of 
the matrix by MMP activity is essential to the invasion of blood vessels as it removes transverse 
cartilage septae that would otherwise prevent longitudinal vessel ingrowth. Moreover, matrix 
removal provides space for chondrocytes to expand into as they undergo hypertrophy. In addition 
to this degradation, osteoclasts are also recruited alongside blood vessels and play a crucial role 
in the resorption of the mineralized matrix, thereby helping to create the medullary cavity found 
in long bone a diaphysis (Mackie et al., 2008).  
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Figure 3. Zonal chondrocyte arrangement at growth plates. Chondrocytes adopt morphologically 
distinct maturational zones and maintain a spatially fixed position allowing post-natal limb 
lengthening by driving continued expansion of the primary and secondary ossification centres. 
From distal to proximal, in relation to the invading ossification front, the pattern consists of 
resting chondrocytes, flattened proliferating chondrocytes in a columnar orientation that will 
dictate the longitudinal direction of bone growth, expanded hypertrophic chondrocytes and 
apoptotic chondrocytes. Finally the calcified cartilage and the primary spongiosa mark the 
chondroosseous junction.  
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The second key process during endochondral ossification is vascularization of the developing 
bone. VEGF, is one of the key pro-angiogenic factors involved in ECO and its role during bone 
development has been widely study both in vitro and in vivo (Dai and Rabie, 2007). It is 
fundamental in the recruitment of blood vessels and studies have also shown that it may also 
mediate recruitment of osteoclasts (Nakagawa et al., 2000). This growth factor is expressed in at 
least 6 isoforms which are either bound to the ECM or found in soluble form. Murine VEGF-
120, one of the soluble forms, diffuses into the local environment to set up a concentration 
gradient that is responsible for epiphyseal vascular invasion as well as chondrocyte survival. The 
VEGF-164 isoform is highly expressed by chondrocytes and isfound in a soluble form as well as 
bound to the cartilage ECM. Influxing osteoclasts and locally released MMPs degrade the 
hypertrophic cartilage matrix to release this heparin-bound form of VEGF-making it bioavailable 
(Vu and Werb, 2000). The higher local concentration of VEGF created by this release 
perpetuates the VEGF gradient emanating from the hypertrophic zone and causes the purposeful 
directional recruitment of the ossification front.  It also helps to mediate chondrocyte growth and 
survival on the perichondrium. The VEGF-188 isoform is also bound to the ECM and is 
responsible for vascular invasion of the metaphysis (Goldring et al., 2006). Angiopoietins are 
another set of angiogenic factors that are involved in neo-vascularization. Angiopoietin-1 and -2 
are responsible for vascular invasion during fracture healing. The angiopoietin receptors: Tie-1 
and -2 are also known to be up-regulated during the fracture healing (Goldring, 2006, 
Gerstenfeld et al., 2003, Lehmann et al., 2005). Overall, further information is still needed in 
order to mimic the natural occurrence of these pro-angiogenic and pro-remodeling factors for TE 
construct degradation. However, the development of systems that promote their own degradation 
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and vascularisation would be advantageous, particularly in large defects requiring voluminous 
grafts which are at an increased risk of avascular necrosis and construct failure. 
 
1.4. Recapitulating embryological bone development for bone defect repair 
Recently, the concept of recapitulating embryological processes has been adopted in the field of 
TE in what has been coined as ‘developmental engineering’ to produce paradigms for tissue 
repair (Lenas et al., 2009) In particular, strategies have been employed to mimic the process of 
ECO for bone defect repair application (Oliveira et al., 2009a, Oliveira et al., 2009b, Gawlitta et 
al., 2010, Farrell et al., 2011, Huang et al., 2006). The primary question centered among such 
studies is whether cells driven towards late stage hypertrophy following chondrogenesis in vitro 
can support mineralized tissue formation with features of native bone subsequent to implantation 
in an in vivo environment. Varieties of cell sources, biomaterials, as well as soluble biochemical 
factors have been widely investigated to reproduce this process both in vitro and in vivo and will 
be explored in the following sections. 
 
1.4.1 Cell sources for endochondral bone tissue engineering strategies 
Several cell types are being investigated in the development of tissue-engineered cartilage 
templates in vitro with subsequent in vivo application for bone formation. Adult Mesenchymal 
stem cells (MSCs) are considered as a promising source of cells in TE and numerous sources 
such as those derived from adipose tissue, infrapatellar fat pad, bone marrow and synovium have 
shown success in bone TE {Buckley, 2010 #281;Meyer, 2010 #236;Vinardell, 2012 #79}. Such 
success can be attributed to their multi-potency, ability to secrete a range of cytokines and 
growth factors which mediate cellular activity and suppress immunological response through 
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inhibition of TNF-α and IFN-γ secretion (Devine et al., 2001; Beyth et al., 2005; Pittinger et al., 
1999; Caplan, 2007).  However, MSCs derived from the bone marrow have been the most 
frequently investigated source of progenitor cells for in vivo endochondral tissue engineering to-
date. This is in part due to their potential to differentiate into chondrocytes and subsequently 
progress towards a hypertrophic phenotype in vitro (Hellingman et al., 2010). Furthermore, these 
cells are naturally found in the bone marrow microenvironment in a perivascular niche and are 
released locally or recruited systemically during trauma, thus, they are more likely to respond 
favorably to signals associated with tissue damage, inflammation and ultimately bone repair 
(Caplan and Correa, 2011). MSCs may also alleviate the need for use of additional growth 
factors and cytokines due to their well-documented capacity to secrete bioactive molecules that 
mediate differentiation and immunological responses (Zhu and Huangfu, 2013, Hellingman et 
al., 2010, Thomson et al., 1998, Pittenger et al., 1999). Moreover their low immunogenic activity 
and immunosuppressive properties are of significant advantage for clinical translation (Law and 
Chaudhuri, 2013, De Miguel et al., 2012). 
 
A number of other cell sources have been investigated for endochondral bone TE including both 
chondrocytes and chondrocyte-like cells. However, the results observed with adult chondrocytes 
for bone formation have not been as encouraging as those seen with MSCs. Primary porcine 
chondrocytes seeded onto polycaprolactone (PCL) / BMP-2scaffolds have shown the ability to 
produce cartilage matrix with mRNA expression of the hypertrophic marker COL X (Jeong et 
al., 2012). However, in vivo s/c assessment of this system did not result in significant formation 
with ossification being limited to the external aspect of the scaffolds. Human articular 
chondrocytes (HACs) have also been driven towards a hypertrophic phenotype with the use of 
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micromass culture (Narcisi et al., 2012). However, these cells also  synthesized only poor levels 
of bone tissue when implanted in vivo  and their use in 3D endochondral bone tissue engineering 
may be limited by their stable phenotype (Vacanti et al., 1995), the risk of arthritic development 
subsequent to procurement (Boyce et al., 2013, Schindler, 2011) and slow ex vivo expansion (Lin 
et al., 2008, Oshin et al., 2007). As any alternative, chondrogenic cells such as the ATDC5 cell 
line isolated from mouse teratocarcinoma fibroblastic cells (Weiss et al., 2012) and chick embryo 
sternal chondrocytes with a transient phenotype (Oliveira et al., 2009a, Oliveira et al., 2009b) 
have been used to engineer cartilage in vitro resulting in subsequent bone formation in vivo. 
These cells therefore represent valuable models that will allow in-depth exploration of the 
process of ECO in tissue-engineered cartilage constructs and also the in vivo response to such 
systems.   
 
Embryonic stem cell-derived embryoid bodies have also shown ability to produce cartilage for 
endochondral bone formation following seeding onto ceramic particles and culture in serum-free 
chondrogenic differentiation medium for 21days (Jukes et al., 2008). Upon subcutaneous 
implantation of these constructs bone formed in areas surrounding hypertrophic chondrocytes 
and mineralized cartilage matrix. However, ethical and moral objections, tumorigenicity and 
teratoma formation, challenges related to scaling up production of large cell numbers, genetic 
instability and immunogenic difficulties make them a less viable option in the short to medium 
term (Jung et al., 2012, Puri and Nagy, 2012). A novel source of autologous cells for 
endochondral tissue formation in the future might be fracture haematoma-derived cells, 
previously shown to contain multilineage progenitor cells with similar cell-surface antigen 
profiles to BMSCs (Oe et al., 2007). These cells can be easily retrieved during surgery for 
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fracture repair and have recently been shown to contain a cell population with the potential to 
undergo chondrogenesis, hypertrophy and calcification in vitro (Koga et al., 2013). Despite the 
potential shown by several cell types for endochondral  bone formation, the optimal cell source 
has yet to be identified. 
 
1.4.2 Biomaterials used for endochondral bone tissue engineering strategies 
Biomaterial scaffolds are used to create a three-dimensional environment that acts as a template 
to support cell interaction, proliferation and differentiation with maintenance of a desired 
phenotype and function. To achieve this, a biomaterial should possess appropriate cues, based on 
the native tissue, such as biochemical, architectural and mechanical characteristics that facilitate 
these desired cell responses (Mahmoudifar and Doran, 2012). However, having the ideal 
equilibrium between these characteristics has proven complex. An optimal biomaterial 
composition should provide suitable cues in order to enhance cellular attachment and subsequent 
differentiation. In particular, the ligand binding sites with specific RGD sequences provided by a 
particular material may affect cellular functions such as adhesion, spreading and differentiation 
(Sukmana, 2012). Scaffold architecture is another well recognized determinant of cellular 
function such as adhesion, migration and matrix deposition and may significantly affect 
construct vascularisation (Boccaccini et al., 2012, Sukmana, 2012, Tian and George, 2011). 
Therefore, scaffold architecture may play a key role in the success of tissue-engineered 
endochondral constructs by allowing vessel invasion in vivo.  Whilst hydrogels have been widely 
used in bone TE, their success may be affected by lack of a porous nature subsequently resulting 
in limited perfusion and reduced cellular migratory capacity. To overcome this, researchers have 
attempted to incorporate channels within the hydrogels in order to improve perfusion (Sheehy et 
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al., 2011). Scaffold mechanical properties such as substrate stiffness are known to affect in vitro 
lineage specification such as MSC chondrogenesis and osteogenesis (Steward et al., 2013, 
Murphy et al., 2012, Kelly and Jacobs, 2010, Engler et al., 2006). Indeed it has been shown that 
more compliant scaffolds support differentiation towards a chondrogenic lineage in vitro, while 
stiffer substrates support development of a hypertrophic phenotype both in vitro and in vivo 
(Bian et al., 2013). Therefore, such properties need to be taken into consideration when 
developing scaffolds suitable for endochondral bone tissue engineering. 
 
A number of distinct biomaterials have been developed using a range of naturally-derived and 
synthetic polymeric materials and have been shown to support MSC chondrogenesis in vitro 
(Table 1). In our laboratory, collagen typically is the primary constituent of scaffolds for tissue 
regeneration including bone and cartilage (O’Brien et al., 2005; Tierney et al., 2009; Matsiko et 
al., 2012). Similarly, other collagen-based scaffolds have been widely used for both in vitro and 
in vivo tissue engineering and in particular endochondral bone formation with varying success 
(Scotti et al., 2013, Glatt et al., 2012, Rivron et al., 2012, Weiss et al., 2012, Farrell et al., 2011, 
Farrell et al., 2009, Oliveira et al., 2009b, Yu et al., 2010). Part of their success could be 
attributed to their biocompatibility, biodegradability, presence of functional motifs that facilitate 
tissue regeneration and vessel development (Duffy et al., 2011, Tian and George, 2011, 
Sukmana, 2012, Yannas et al., 1989, Burke et al., 1981).  
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Biomaterial Cell Source Evaluation Reference 
Alginate Human, bone marrow derived 
 
Human 
Gene expression, histology, SEM, GAG 
content 
Gene expression 
(Wang et al., 2009) 
 
(Xu et al., 2008) 
Alginate (RGD-modified) Human, bone marrow derived Biochemical analysis, gene expression, 
histology 
(Re'em et al., 2010) 
Agarose Porcine, bone marrow  
 
 
Porcine, bone marrow, 
infrapatellar fat pad and synovial 
membrane derived 
 
Bovine, bone marrow derived 
Biochemical analysis, histology, 
immunohistochemistry micro-computed 
tomography, in vivo  
Biochemical analysis, histology, 
immunohistochemistry,  micro-
computed tomography mechanical 
properties, in vivo 
Biochemical analysis, histology, 
mechanical properties 
(Sheehy et al., 2013) 
 
 
(Vinardell et al., 2012) 
 
 
 
(Mauck et al., 2006) 
 
Chitosan  Human, adipose and placenta 
derived 
 
Human, bone marrow and 
adipose derived 
Biochemical analysis, gene expression, 
histology 
 
Gene expression, histology, SEM 
(Huang et al., 2011) 
 
 
(Seda Tigli et al., 2009) 
Collagen type I Human, bone marrow derived 
 
 
Human, umbilical cord derived 
Biochemical analysis, gene expression, 
histology, micro-computed tomography, 
in vivo 
Biochemical analysis, gene expression, 
histology 
(Scotti et al., 2013) 
 
 
(Chen et al., 2013) 
Collagen type I / GAG Rat, bone marrow derived  
 
 
Human, bone marrow derived 
 
 
Human, bone marrow derived 
Biochemical analysis, gene expression, 
histology, immunohistochemistry, 
mechanical properties 
Gene expression, histology, 
immunohistochemistry,  micro-
computed tomography, in vivo  
Histology, immunohistochemistry , in 
vivo 
(Matsiko et al., 2012) 
 
 
(Farrell et al., 2011) 
 
 
(Farrell et al., 2009) 
 
Collagen type II Human, bone marrow derived Histology (Chang et al., 2007)  
Fibrin Human, bone marrow derived 
 
Human, bone marrow derived 
 
Biochemical analysis, gene expression, 
histology 
Biochemical analysis, gene expression, 
histology 
(Ho et al., 2010) 
 
(Dickhut et al., 2008) 
Hyaluronic acid Human, bone marrow derived 
 
Goat, bone marrow derived 
 
Biochemical analysis, gene expression, 
histology, mechanical properties, in vivo 
Biochemical analysis, gene expression, 
histology, mechanical properties 
(Bian et al., 2013) 
 
(Toh et al., 2012)  
Hyaluronan / Gelatin 
 
Rabbit, bone marrow derived 
 
Histology, immunohistochemistry, in 
vivo 
(Huang et al., 2006) 
Matrigel Human, bone marrow derived 
 
Biochemical analysis, gene expression, 
histology 
(Dickhut et al., 2008) 
Poly lactic-co-glycolic acid 
(PLGA) / Poly(ε-
caprolactone) (PCL)  
nanofifiber scaffold 
Rat, bone marrow derived 
 
Biochemical analysis, histology, SEM, 
in vivo 
 
(Yang et al., 2013) 
Poly(ethylene glycol) (PEG) Human, bone marrow derived 
 
Biochemical analysis, histology, 
immunohistochemistry 
(Buxton et al., 2007) 
Poly(ethylene oxide) 
diacrylate (PEODA) with 
collagen mimetic peptides 
Goat, bone marrow derived 
 
Biochemical analysis, gene expression, 
histology 
 
(Lee et al., 2008) 
Polygylcolic acid (PGA) Rabbit, bone marrow derived Histology, immunohistochemistry (Zhou et al., 2008) 
Poly(l-lactic acid) (PLLA) 
nanofiber scaffolds 
Human, bone marrow derived 
 
Gene expression, histology, mechanical 
properties 
(Janjanin et al., 2008) 
Silk fibroin scaffold Human, bone marrow and 
adipose derived 
Biochemical analysis, histology (Seda Tigli et al., 2009) 
Sulfonate-coated 
polyacrylamide (S-PAAm) 
gels 
Mouse, bone marrow derived Gene expression, histology (Kwon, 2013) 
Table 1. The table shows a list of scaffolds that have shown potential to support cartilage-like 
matrix deposition and may be suitable candidates for the development of cartilage templates for 
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endochondral bone formation. Modified and reprinted from J Biomec, Vol 43(1), Huang AH, 
Farrell MJ, Mauck RL, Mechanics and mechanobiology of mesenchymal stem cell-based 
engineered cartilage, Pages No. 128-36, Copyright  2010, with permission from Elsevier 
 
Other approaches for the fabrication of scaffolds for ECO applications in the future may include 
the use of decellularized constructs that can maintain the native 3D architecture, porosity and 
importantly the ECM components with appropriate cues that facilitate biological signaling 
(Arenas-Herrera et al., 2013). This technique has already led to clinical translation for human 
airway tissue repair applications (Macchiarini et al., 2008). Recently, decellularized matrices 
have been used as platforms for vascular graft development (Sheridan et al., 2012) and reported 
to support human articular chondrocytes and human bone marrow-derived MSC (hBMSC) 
chondrogenic differentiation and synthetic activity for cartilage regeneration (Giavaresi et al., 
2013). 
 
1.5  In vitro incubation periods to promote maturation and hypertrophy for 
endochondral bone tissue engineering 
One of the major challenges to ECO-based strategies for bone formation is identifying the 
optimal in vitro cultivation period and conditions prior to implantation. Research to date shows 
the heterogeneous approaches taken in terms of in vitro incubation periods in order to facilitate 
MSC-derived chondrocytic maturation and hypertrophy prior to implantation (Table 2). 21 days 
of culture in TGF-β-supplemented chondrogenic differentiation media alone has been shown to 
stimulate MSCs differentiating towards late stage chondrogenesis, hypertrophy and subsequent 
bone formation in vivo (Sheehy et al., 2013, Vinardell et al., 2012, Pelttari et al., 2006, Huang et 
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al., 2006). However, studies have shown that either an additional 7 days of culture in the 
presence of β-glycerol-phosphate (β-GP) only (28 days in total) (Farrell et al., 2011) or an 
additional 14 days of culture in the presence of β-GP and thyroxine (35 days in total) (Mumme et 
al., 2012, Scotti et al., 2013, Scotti et al., 2010) have also stimulated bone formation in vivo.  
 
Depending on the culture regime and in vitro incubation period used, differing stages of cartilage 
maturity and hypertrophy at the time of implantation can be achieved. A recent study 
investigated the impact of cartilage maturation on subsequent bone formation following 
implantation using three distinct groups (Scotti et al., 2010). Pre-hypertrophic and early 
hypertrophic groups were formed from hBMSC transwell constructs which were cultured in 
chondrogenic media for 1 and 2 weeks respectively. The late hypertrophic group was formed 
from the same hBMSC transwell contructs but had undergone 3 weeks of culture in 
chondrogenic media followed by an additional 2 weeks of culture in thyroxine-supplemented 
media. The culture periods showed progressively more mature cartilage formation in vitro with 
respect to culture length. Moreover, following subcutaneous implantation, template maturation 
correlated with bone formation and similar gene profiles to those seen in embryonic long bone 
development such as IHH, PTHrP and BMPs (Scotti et al., 2010). However, delayed 
implantation or prolonged in vitro culture may fail to take advantage of such genes and proteins 
that facilitate endochondral bone formation (Jeong et al., 2012). Furthermore, another study 
demonstrates the potential risk of using more mature, metabolically active hypertrophic cells 
with a shorter bioactive lifespan compared to immature pre-hypertrophic cells with lower 
nutritional and oxygen requirements (Gawlitta et al., 2010). Taken together, it is clear that the in 
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vitro culture duration prior to implantation needs to be standardised in order to facilitate 
enhanced chondrocyte hypertrophy and subsequent bone formation through ECO. 
 
1.5.2 In vitro regulation of hypertrophy for endochondral bone tissue engineering 
A wide range of cytokines and growth factors have utilized by a number of studies in order to 
drive MSCs towards a hypertrophic phenotype. However, there is a general lack of 
standardization with regards to the ideal culture conditions prior to in vivo implantation. The 
bone marrow contains a plethora of growth factors, cytokines and cells that are crucial in the 
homeostasis of bone and cartilage tissue. Some of these growth factors include bone 
morphogenetic proteins (BMPs). Whilst isoforms of BMP such as BMP-2 are fundamental in 
early stage mesenchymal stem cell chondrogenic differentiation and maintenance of a 
chondrocytic phenotype, such growth factors are also involved in regulating terminal 
differentiation (Goldring, 2006). A different isoform, BMP-6 is also involved in mediating 
chondrocyte hypertrophy. Treatment of chondrocytes with BMP-6 has been widely shown to 
stimulate gene expression of COLX, demonstrating the role of such a growth factor in ECO 
(Grimsrud et al., 1999, Grimsrud et al., 2001). The use of other supplemental growth factors in 
vitro to promote chondrocyte hypertrophy will be discussed below. 
 
Transforming growth factor-beta 1, 2 and 3 (TGF-β1, TGF-β2 and TGF-β3), members of the 
TGF-β super family, have also been shown to play crucial roles in cartilage and endochondral 
bone formation during fracture healing (Marsell and Einhorn, 2011, Gerstenfeld et al., 2003). In 
vitro exposure to such factors can induce chondrogenesis, proliferation and matrix deposition in 
MSCs with eventual progression towards hypertrophy (Mueller et al., 2010, Johnstone et al., 
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1998). This is mediated through complex interactions with members of the fibroblast growth 
factor (FGF) and wingless-type (Wnt) protein families (Cleary et al., 2013). TGF-β subtypes in 
the presence of additional factors, such as thyroid hormone have been used to accelerate MSC-
derived chondrocytes towards hypertrophy following only 14 days of chondrogenic-priming 
(Mueller et al., 2010, Mueller and Tuan, 2008). However, (Farrell et al., 2009) and (Pelttari et al., 
2006) have shown that MSCs incubated in TGF-β2 and TGF-β3 respectively could promote the 
expression of genes associated with chondrogenesis and hypertrophy as well as factors critical to 
vascularization such as vascular endothelial growth factor (VEGF) and matrix metalloproteinases 
(MMPs) without the need for other additional factors such as thyroid hormones. Furthermore, the 
different TGF-β subtypes have been shown to influence the level of mineralization in pellet 
culture without significant differences in collagen type X staining or VEGF secretion within 
media samples (Cals et al., 2012). Significantly higher levels of mineralization were observed in 
vitro in hypertrophic hBMSC-derived chondrocyte pellets cultured in TGF-β3 with the addition 
of β-GP than in a TGF-β1/β-GP treated group (Cals et al., 2012), while TGF-β2 
chondrogenically-primed hBMSCs underwent mineralization in vitro in the presence of β-GP, 
without significant differences in the expression of hypertrophic markers compared to untreated 
groups (Farrell et al., 2009).  
 
Another type of growth factor involved in mediating hypertrophy is insulin growth factor (IGF). 
IGF-1 and -2 are required in chondrocyte proliferation and hypertrophy. A study utilizing IGF-
receptor1 knockdown mice demonstrated that their growth was significantly stunted (Baker et 
al., 1993). It is also now known that IGF-1 is involved in growth hormone activity. Growth 
hormone is responsible for longitudinal bone growth. A study elegantly demonstrated that a 
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reduction in IGF-1 levels correlated with interstitial growth of long bones in mice (Yakar et al., 
2002). It is suggested that growth hormone activity is dependent on localized IGF-1 production 
(Nilsson et al., 2005).  
  
Thyroid hormone works in synergy with the growth hormone and is also involved in hypertrophy 
and growth of bones. It has been widely used both in vitro and in vivo and has been shown to 
support MSC chondrogenesis and maturation. The thyroid hormone derivatives triiodothyronine 
(T3) and thyroxine (T4) have been shown to stimulate enlargement of chondrocytes, thereby 
regulating hypertrophy and secretion of collagen type X and alkaline phosphatase activity 
(Ahmed et al., 2007). The T4 isoform of thyroid hormone has also been used to enhance 
hypertrophy of MSC-derived chondrocytes following 21 days of chondrogenic-priming with 
TGF-β1 (Scotti et al., 2013, Mumme et al., 2012, Scotti et al., 2010).  
 
Trans-retinoic acid, a metabolite of vitamin A, has been shown to support maturation, 
hypertrophy and cartilaginous tissue formation by chick embryo chondrocytes on both collagen 
and chitosan scaffolds in vitro (Palmer et al., 2010, Oliveira et al., 2009a, Oliveira et al., 2009b, 
Oliveira et al., 2010, Teixeira et al., 2006), possibly through its action on retinoic acid receptors 
(RAR) causing down regulation of  Indian Hedgehog (IHH) and upregulation of RARγ, MMP13 
and Runx2 gene expression to promote hypertrophy and bone formation (Williams et al., 2010, 
Koyama et al., 1999). Although this system has not been assessed with MSC-derived 
chondrocytes, RAR-γ is highly expressed by MSC-derived chondrocytes under T3 hypertrophic 
conditions with β-GP (Mueller and Tuan, 2008) and could offer an alternative culture regime for 
endochondral bone tissue engineering. Other approaches including adenoviral vectors encoding 
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for IHH (Steinert et al., 2012), bone morphogenetic protein-2 and -4 (BMP-2, BMP-4) and TGF-
β1 (Palmer et al., 2005) have all shown the ability to induce chondrogenesis in hBMSC pellets as 
early as 3 weeks in vitro, while soluble mediators such as vitamin D3 (Dreier et al., 2008, 
Gerstenfeld and Shapiro, 1996, Boyan et al., 1992) and leptin (Wang et al., 2012, Wang et al., 
2011) have also been shown to favorably influence in vitro chondrocyte hypertrophy.  
 
The use of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) may be beneficial in 
the process of endochondral bone formation and template remodeling (Scotti et al., 2013, 
Mumme et al., 2012). MSC-seeded collagen constructs cultured with IL-1β led to in vitro up-
regulation of genes associated with chondrogenesis and hypertrophy (Scotti et al., 2013). In 
addition to increased MMP-13 activity and tartrate-resistant acid phosphatase (TRAP) activity 
compared to controls, bone formation was enhanced in vivo. Overall, these data imply enhanced 
endogenous and host mediated-ECM degradation in response to IL-1β which could be beneficial 
in the degradation of larger constructs needed to facilitate clinically relevant bone regeneration in 
vivo. Furthermore, encouraging a hypertrophic phenotype in a cartilage template for bone 
formation may promote implant degradation as these hypertrophic cells can release lysosomal 
hydrolases involved in growth plate cartilage degradation in vivo (Bastow et al., 2012). 
 
1.6 Current in vivo models of endochondral ossification 
Following encouraging in vitro results involving several different biomaterials, a number of 
studies have examined the in vivo potential of tissue engineered cartilage templates for ECO 
bone formation (Table 2). In addition, recent work in our laboratory has demonstrated 
chondrogenesis with subsequent bone formation in vivo using alginate-based constructs in a 
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subcutaneous model (Fig. 4).  Indeed, the majority of studies published thus far, have utilized 
subcutaneous models to determine the in vivo efficacy of their constructs for endochondral bone 
formation (Farrell et al., 2009, Sheehy et al., 2013, Farrell et al., 2011, Pelttari et al., 2006). The 
ectopic subcutaneous environment offers a reproducible, easily accessible location for in vivo 
validation. However, in order to fully determine the potential of constructs for endochondral 
ossification, osseous defect models should be utilized. One of the earliest studies to assess the in 
vivo potential of cartilage constructs for bone formation used a distinct in vivo model with the 
excision of an entire bone (Huang et al., 2006). The authors investigated the potential of an 
autologous cartilage construct derived from MSCs for carpal bone reconstruction following 
lunate excision in the rabbit forelimb. This was the first time that whole-bone repair was 
attempted and the study demonstrated that the cartilage construct was capable of supporting 
woven bone tissue formation following 12 weeks of implantation. Moreover, the study also 
demonstrated presence of neo-vascularization following implantation demonstrating the potential 
of such cartilage-based systems to promote blood vessel ingrowth. To further translate the 
potential of ECO-based strategies for therapeutic applications more investigation into clinically 
relevant bone defect models is required. There are now a number of well recognized weight-
bearing segmental bone defects models established on small animals which should be adopted 
for the validation and assessment of ECO-based strategies. Our laboratory has recently adopted a 
rat femoral segmental defect model and the evaluation of a number of biomaterials for 
endochondral bone formation is currently underway.  
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Figure 4. (A) Macroscopic image, (B)collagen type II immunothistochemistry and (C) aldehyde 
fuschin - alcian blue histology of chondrogenically primed MSC seeded alginate hydrogels pre-
implantation. (D) Macroscopic image and (E) haematoxylin and eosin histology of alginate 
constructs 6 weeks post implantation. Macroscopic scales bars 3 mm. Prior to subcutaneous 
implantation constructs had undergone robust chondrogenesis, as indicated by intense staining 
for collagen type II and sGAG (B and C). Post-implantation, H&E staining (E) demonstrated the 
presence of trabecular bone struts, bone marrow foci, and blood vessel infiltration (inset). Images 
courtesy of E. Sheehy. 
 
There has been a wide range of distint approaches adopted for in vivo bone formation based on 
ECO in terms of biomaterials used, cell sources, soluble biochemical factors as well as in vitro 
culture duration, as shown on Table 2.  However, one similarity observed in these studies is the 
use of immune-incompetent mice to assess in vivo potential of the constructs thus far. Whilst this 
is widely accepted, host immunological responses are well known to play a key role in 
remodeling and neo-tissue formation following biomaterial implantation (Badylak and Gilbert, 
2008, Brown et al., 2012). Therefore, the immunological processes that participate in mediating 
the host response to tissue-engineered constructs post-implantation need to be investigated in 
order to validate their potential for clinical translation. 
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Construct Cell type Culture conditions In vivo location & time 
points 
Reference  
3D cell pellet hBMSC  4-5*105 cells / pellet, 3-7 weeks in TGF-
β2 supplemented media  
 
Subcutaneous (SCID 
mice),     4-6 weeks 
(Pelttari et al., 
2006) 
Agarose Hydrogel 
(single layer and 
bilayered) 
 
BMSC and 
HAC, porcine 
20*106 cells / ml, 21 days in TGF-β3 
supplemented media 
Subcutaneous (nude mice),                     
4weeks 
(Sheehy et al., 
2013) 
Electrospun 
PLGA/PCL polymer 
fiber scaffold and 3D 
cell pellet 
 
BMSC, rat 1*106 cells / scaffold, 28 days in TGF-β2 
and BMP-2 supplemented media 
Subcutaneous (nude mice),                     
8 weeks 
(Yang et al., 2013) 
Chitosan scaffold Chondrocytes, 
chick embryo 
sternum 
20*104 cells / scaffold, 10 days in 
hyaluronidase and ascorbic acid 
supplemented media followed by:             
- 10 days with the addition  of all-trans 
retinoic acid 
 
Subcutaneous (nude mice),        
1, 2, 3, 4, and 5 months                  
(Oliveira et al., 
2009b) 
Collagen-GAG 
scaffold 
hBMSC 30*104 cells / scaffold,  21 days in TGF-
β2 supplemented media 
 
Subcutaneous (nude mice),                     
4 weeks 
(Farrell et al., 
2009) 
 hBMSC 1*106 cells / scaffold, 21 days in TGF-β2 
supplemented media followed by:                                                                             
- 7 days in TGF-β2 media or                                      
- 7 days in TGF-β2 media with the 
addition of β-glycerophosphate 
 
Subcutaneous (nude mice),                     
8 and 14 weeks 
(Farrell et al., 
2011) 
Collagen type I mesh hBMSC 40*106 cells / cm3, 21 days in TGF-β1 
with IL-1β supplemented media followed 
by:                                                               
- 14 days in hypertrophic media without 
TGF-β1 but supplemented with thyroxine, 
β-glycerol phosphate, dexamethasone and 
L-ascorbic acid-2-phosphate 
 
Subcutaneous (nude mice),                     
5 and 12 weeks 
(Mumme et al., 
2012) 
 hBMSC 70*106 cells / cm3, 21 days in TGF-β1 
supplemented media followed by 14 days 
in hypertrophic media without TGF-β1 
but supplemented with thyroxine, β-
glycerol phosphate 
 
Subcutaneous (nude mice),                     
5 and 12 weeks 
(Scotti et al., 2013) 
Hyaluronan / Gelatin 
 
 
BMSC, rabbit 1*105 cells/ μl, 21 days in TGF-β1 
supplemented media 
Lunate excision 
arthroplasty (rabbit), 6 and 
12 weeks 
 
(Huang et al., 
2006) 
Polylactic acid coated 
polyglycolic acid 
scaffold 
 
hBMSC 2.5*106 cells / scaffold, 4, 8 and 12 weeks 
in TGF-β1 supplemented media 
Subcutaneous (nude mice),                     
12 and 24 weeks 
(Liu et al., 2008) 
Transwell plate self 
assembly 
hBMSC 5*105 cells / insert:                                                    
- 7 days in TGF-β1 supplemented media 
or                                                                
- 14 days in TGF-β1 supplemented media 
or                                                                
- 21 days in TGF-β1 supplemented media 
followed by 14 days in hypertrophic 
media without TGF-β1 but supplemented 
with thyroxine, β-glycerol phosphate 
 
Subcutaneous (nude mice),                     
4 and 8 weeks 
(Scotti et al., 2010) 
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Table 2. Examples of tissue-engineered cartilage that have resulted in in vivo bone formation 
following an endochondral progression including construct type, cell type, culture conditions, 
additional supplements to promote ECO, implantation site and in vivo incubation periods 
 
An important aspect of in vivo assessment is the contribution of donor and host cells to 
endochondral bone formation following implantation of constructs for ECO bone formation. 
Until recently, there have been few studies investigating the retention of implanted cells within 
endochondral grafts and their contribution to neo-tissue formation in such systems. However, it 
now appears that MSCs used in endochondral TE not only play a pivotal role in contributing to 
early tissue formation directly but also act to recruit specific host cell populations and secrete 
trophic factors that influence the process of vascularization and bone formation. Using MSC-
derived cartilage templates, (Farrell et al., 2011) showed that implanted MSCs play a direct role 
in early osteogenesis, with host osteoblasts acting as the main contributors to continued bone 
formation. Using in situ hybridization for human DNA sequences (human Alu repeats), studies 
have also shown that following implantation of MSC-derived cartilage precursors, MSCs 
initially intersperse with host cells and contribute directly to bone formation in vivo (Scotti et al., 
2013, Scotti et al., 2010, Pelttari et al., 2006). Moreover, implanted donor cells have been shown 
to further co-localize specifically to inner regions of endochondral bone formation with 
osteoblast- and osteocyte-like cells (Scotti et al., 2013). Conversely, the outer regions of these 
constructs were observed to be characteristic of cortical-like bone and contained only host cells 
(Scotti et al., 2013). MSCs are known to recruit host cells and this was demonstrated by (Tortelli 
et al., 2010) using MSC-seeded scaffolds which stimulated bone and blood vessel formation via 
an endochondral-like process by recruiting host-derived CD31+ endothelial cells. Moreover, 
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compared to osteoblast-seeded scaffolds, the MSC-seeded scaffolds stimulated greater neo-
vascularisation following implantation. Furthermore, analysis of this process was carried out by 
(Tasso et al., 2010) who investigated the nature of recruited host cells and demonstrated 
consecutive recruitment of two distinct waves of host cells: (i) CD31+ endothelial progenitors 
capable of tubule formation and (ii) CD146+ cells that displayed characteristics of MSCs. Their 
findings suggest that donor MSCs can act as both a cell source for chondro- and osteogenesis, as 
well as a co-ordinator for angiogenic-osteogenic coupling needed for bone generation and may 
help to explain the results from the above studies. 
 
1.7 Future directions and concluding remarks 
The evolution of strategies to repair bone defects using a tissue engineering approach has led to 
an ever-growing interest in recapitulating the embryological process of endochondral ossification 
in what is now coined as ‘developmental engineering’. This concept has been motivated by the 
hypothesis that cells driven through a chondrogenic lineage can secrete cartilaginous tissue that 
can act as a template for bone formation. In particular, hypertrophic chondrocytes can secrete 
angiogenic factors and alkaline phosphatase which play pivotal roles in both the vascularization 
of constructs in vivo and the deposition of a mineralized extracellular matrix with resulting bone 
deposition. Ultimately, this conveys great significance with regards to overcoming the 
drawbacks associated with a multitude of tissue-engineered constructs characterised by poor 
perfusion and avascular necrosis. However, several pivotal questions still remain to be answered 
including the optimal cell source, biomaterial scaffold and in vitro culture conditions required to 
produce robust chondrogenesis and hypertrophy in vitro with subsequent bone formation in vivo. 
Taken together, recapitulating endochondral ossification to develop such constructs for bone 
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defect repair is still in its nascency but it offers an attractive alternative to traditional bone tissue 
engineering strategies. 
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